347P Chemotherapy (CT) and GnRH analogue (a) benefit in patients (pts)≤50 years (y) with estrogen receptor-positive (ER+)/HER2-negative (-) stage I–II breast cancer (BC) risk-stratified by ProsignaF. Schettini, G Grazia, Vincenzo Di Lauro et al.|Annals of Oncology|2025Cited by 0